Wistedt B, Agren H, Bjaring B, Källström B, Lund M, Månsby J, Peterson L E, Roos B E
Acta Psychiatr Scand. 1983 Sep;68(3):212-20. doi: 10.1111/j.1600-0447.1983.tb07000.x.
Nomifensine, an antidepressive agent acting like a dopamine agonist, was investigated in a randomized double-blind comparison with amitriptyline in 29 patients fulfilling the RDC criteria for major depression. The dosage was 150 mg daily in both treatment groups. Assessments were made at weekly intervals for 6 weeks with the Comprehensive Psychopathological Rating Scale. No significant difference could be demonstrated between the two drugs in overall therapeutic efficiency, and only one item, Fatiguability, differed significantly in favour of amitriptyline. Physical and laboratory variables showed no statistically significant differences. Neither drug elicited serious unwanted effects.
诺米芬辛是一种作用类似多巴胺激动剂的抗抑郁药，在29例符合精神疾病诊断与统计手册（RDC）中重度抑郁症标准的患者中，进行了一项与阿米替林的随机双盲对照研究。两个治疗组的剂量均为每日150毫克。使用综合精神病理学评定量表，每隔一周进行一次评估，为期6周。两种药物在总体治疗效果上没有显著差异，只有一项“易疲劳性”有显著差异，阿米替林更具优势。身体和实验室指标没有统计学上的显著差异。两种药物均未引发严重的不良反应。
